BTBD14A Inhibitors
Chemical inhibitors of BTBD14A encompass a range of compounds that interfere with various cellular signaling pathways, indirectly leading to the inhibition of BTBD14A activity. MG-132, a proteasome inhibitor, can lead to the accumulation of proteins that negatively regulate BTBD14A, thus functionally inhibiting it. Similarly, Y-27632, through its action as a ROCK inhibitor, can disrupt cytoskeletal dynamics, which could be crucial for BTBD14A's role, resulting in its inhibition. SB203580, by inhibiting p38 MAPK, and PD98059, an ERK inhibitor, both target the MAPK signaling pathway. The inhibition of these kinases can suppress the activation of downstream targets, including BTBD14A, if it is regulated by this pathway. LY294002 and Wortmannin, both PI3K inhibitors, can prevent the activation of the PI3K/Akt pathway, potentially suppressing BTBD14A activity if it is PI3K/Akt-dependent. SP600125 acts on the JNK signaling pathway, where its inhibition could lead to reduced BTBD14A activity, assuming BTBD14A operates downstream.
In addition to these, GF109203X and Gö 6983, both inhibitors of protein kinase C (PKC), could reduce BTBD14A activity by blocking PKC-mediated signaling pathways, which may be essential for the activation of BTBD14A. U0126, another MEK1/2 inhibitor, can prevent the activation of the MEK/ERK pathway, thereby potentially inhibiting BTBD14A if it is downstream of this pathway. Rapamycin, an mTOR inhibitor, disrupts mTOR signaling, a pathway that could be critical for BTBD14A's function in cell growth and proliferation, thus indirectly inhibiting its activity. Lastly, KN-93, which selectively inhibits Ca2+/calmodulin-dependent protein kinase II (CaMKII), can decrease BTBD14A activity if BTBD14A is dependent on CaMKII signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can indirectly inhibit BTBD14A by preventing the degradation of proteins that negatively regulate BTBD14A activity. If BTBD14A requires proteasomal degradation of a repressor protein for its function, MG-132 would lead to the accumulation of that repressor, thus inhibiting BTBD14A. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor which can indirectly inhibit BTBD14A if BTBD14A function is regulated through the Rho/ROCK pathway. Inhibition of ROCK could lead to altered cytoskeletal dynamics, potentially affecting BTBD14A's role in chromatin remodeling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which can inhibit BTBD14A if BTBD14A's activity is modulated by p38 MAPK signaling. By inhibiting this kinase, downstream signaling required for BTBD14A activation could be disrupted. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which can inhibit BTBD14A by blocking the PI3K/Akt pathway. If BTBD14A activity is dependent on PI3K/Akt signaling for its function, inhibiting PI3K would suppress BTBD14A activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an ERK inhibitor which can indirectly inhibit BTBD14A by blocking the MEK/ERK pathway. If BTBD14A is activated downstream of ERK signaling, then inhibiting ERK would prevent BTBD14A's functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can reduce BTBD14A activity by inhibiting the JNK signaling pathway. If BTBD14A operates downstream of JNK, then JNK inhibition would suppress the functional activity of BTBD14A. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X is a protein kinase C (PKC) inhibitor that could indirectly inhibit BTBD14A by blocking PKC-mediated signaling pathways. If BTBD14A is activated by PKC, inhibiting PKC would result in the suppression of BTBD14A activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. By inhibiting PI3K, it could prevent the activation of downstream targets that may be necessary for BTBD14A activity, thus functionally inhibiting BTBD14A. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a PKC inhibitor. By inhibiting various PKC isoforms, it can reduce BTBD14A activity if BTBD14A is activated as part of a signaling cascade involving PKC. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it can disrupt the mTOR signaling pathway which may be crucial for BTBD14A's role in cell growth and proliferation, thus indirectly inhibiting BTBD14A. | ||||||